Accessibility

LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.

Hepatitis Be Antigen

CPT: 87350
Updated on 09/23/2020
Print Share

Synonyms

  • HBeAg
  • HBV
  • hepatitis B
  • hepatitis B e-antigen
  • HBeAg
  • <
  • HBeAg
  • HBV
  • hepatitis B
  • hepatitis B e-antigen

Special Instructions

This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.


Expected Turnaround Time

1 - 3 days


Related Documents


Specimen Requirements


Specimen

Serum or plasma


Volume

1.5 mL


Minimum Volume

0.5 mL (Note: This volume does not allow for repeat testing.)


Container

Gel-barrier tube or lavender-top (EDTA) tube


Collection

If tube other than a gel-barrier tube is used, transfer separated serum or plasma to a plastic transport tube.


Storage Instructions

Room temperature

Refrigerate

Room temperature


Stability Requirements

Temperature

Period

Room Temperature

7 days (stability provided by manufacturer or literature reference)

Refrigerated

7 days (stability provided by manufacturer or literature reference)

Frozen

1 year (stability provided by manufacturer or literature reference)

Freeze/thaw cycles

Stable x3 (stability provided by manufacturer or literature reference)

Temperature

Period

Room Temperature

7 days (stability provided by manufacturer or literature reference)

Refrigerated

7 days (stability provided by manufacturer or literature reference)

Frozen

1 year (stability provided by manufacturer or literature reference)

Freeze/thaw cycles

Stable x3 (stability provided by manufacturer or literature reference)

Temperature

Period

Room Temperature

7 days (stability provided by manufacturer or literature reference)

Refrigerated

7 days (stability provided by manufacturer or literature reference)

Frozen

1 year (stability provided by manufacturer or literature reference)

Freeze/thaw cycles

Stable x3 (stability provided by manufacturer or literature reference)

Temperature

Period

Room Temperature

7 days (stability provided by manufacturer or literature reference)

Refrigerated

7 days (stability provided by manufacturer or literature reference)

Frozen

1 year (stability provided by manufacturer or literature reference)

Freeze/thaw cycles

Stable x3 (stability provided by manufacturer or literature reference)

Temperature

Period

Room Temperature

7 days (stability provided by manufacturer or literature reference)

Refrigerated

7 days (stability provided by manufacturer or literature reference)

Frozen

1 year (stability provided by manufacturer or literature reference)

Freeze/thaw cycles

Stable x3 (stability provided by manufacturer or literature reference)


Causes for Rejection

Non-EDTA plasma specimen; heat-inactivated specimens; cord blood; cadaver specimens; or body fluids other than serum or EDTA plasma


Test Details


Use

The HBe antigen assay, in conjunction with other serological and clinical information, can be used for the determination and management of chronic hepatitis B infection. This assay should not be used for the diagnosis of acute Hepatitis B infection.

The HBe antigen assay, in conjunction with other serological and clinical information, is intended only for the determination of chronic infection with hepatitis B virus.

The HBe antigen assay, in conjunction with other serological and clinical information, can be used for the determination and management of chronic hepatitis B infection. This assay should not be used for the diagnosis of acute Hepatitis B infection.


Limitations

This assay has not been FDA-approved for the diagnosis of individuals with acute hepatitis B infection.

Assay performance characteristics have not been established for testing of children less than 17 years of age or pregnant women or in populations of immunocompromised or immunosuppressed patients.

This assay has not been licensed for the screening of blood, plasma, and tissue donors.

Assay performance characteristics have not been established for (1) children younger than 17 years of age, (2) pregnant women, or (3) populations of immunocompromised or immunosuppressed patients.

This assay has not been FDA-approved for the diagnosis of individuals with acute hepatitis B infection.

This assay has not been FDA-approved for the diagnosis of individuals with acute hepatitis B infection.

Assay performance characteristics have not been established for testing of children less than 17 years of age or pregnant women or in populations of immunocompromised or immunosuppressed patients.

This assay has not been licensed for the screening of blood, plasma, and tissue donors.


Methodology

Immunochemiluminometric assay (ICMA)


Reference Interval

Negative


Additional Information

HBe antigen becomes detectable shortly after HBsAg is detectable and is an indicator of active infection and replicating virus. The disappearance of HBeAg and the appearance of anti-HBe together with other HBV markers allow the clinician to determine a prognosis, and to follow the progression of the disease from acute to chronic or recovered status.


References

Abara WE, Qaseem A, Schillie S, et al. Hepatitis B Vaccination, Screening, and Likage to Care: Best Practice Advice from American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2017 Dec 5;167(11):794-804.29159414
Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States. Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018 Jan 12;67(1):1-31.29939980
Terrault NA, Lok ASF, McMahon BJ, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018 Apr;67(4):1560-1599.29405329
Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137.26042815
Edwards MS. Hepatitis B serology−help in interpretation. Pediatr Clin North Am. 1988 Jun; 35(3):503-515 (review). 3287312
Lee HS, Vyas GN. Diagnosis of viral hepatitis. Clin Lab Med. 1987 Dec; 7(4):741-757 (review). 3319367
Mushahwar IK, Dienstag JL, Polesky HF, McGrath LC, Decker RH, Overby LR. Interpretation of various serological profiles of hepatitis B virus infection. Am J Clin Pathol. 1981 Dec; 76(6):773-777. 7315794
Mushahwar IK, McGrath LC, Drnec J, Overby LR. Radioimmunoassay for detection of hepatitis B e antigen and its antibody. Results of clinical evaluation. Am J Clin Pathol. 1981 Nov; 76(5):692-697. 6170222
Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y. e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med. 1976 Apr 1; 294(14):746-749. 943694
Abara WE, Qaseem A, Schillie S, et al. Hepatitis B Vaccination, Screening, and Likage to Care: Best Practice Advice from American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2017 Dec 5;167(11):794-804.29159414
Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States. Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018 Jan 12;67(1):1-31.29939980
Terrault NA, Lok ASF, McMahon BJ, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018 Apr;67(4):1560-1599.29405329
Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137.26042815

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
006619 Hep Be Ag 13954-3 006619 Hep Be Ag 13954-3

For Providers

Please login to order a test

Order a Test

© 2020 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf